Your browser doesn't support javascript.
AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants.
Giesen, Nicola; Busch, Elena; Schalk, Enrico; Beutel, Gernot; Rüthrich, Maria M; Hentrich, Marcus; Hertenstein, Bernd; Hirsch, Hans H; Karthaus, Meinolf; Khodamoradi, Yascha; Koehler, Philipp; Krüger, William; Koldehoff, Michael; Krause, Robert; Mellinghoff, Sibylle C; Penack, Olaf; Sandherr, Michael; Seggewiss-Bernhardt, Ruth; Spiekermann, Karsten; Sprute, Rosanne; Stemler, Jannik; Weissinger, Florian; Wörmann, Bernhard; Wolf, Hans-Heinrich; Cornely, Oliver A; Rieger, Christina T; von Lilienfeld-Toal, Marie.
  • Giesen N; Department of Hematology, Oncology and Palliative Care, Robert Bosch Hospital, Stuttgart, Germany. Electronic address: nicola.giesen@rbk.de.
  • Busch E; Department of Medical Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
  • Schalk E; Department of Hematology and Oncology, Medical Centre, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
  • Beutel G; Department for Haematology, Haemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany; Working Party Intensive Care in Haematologic and Oncologic Patients (iCHOP) of the German Society of Haematology and Medical Oncology (DGHO), Germany.
  • Rüthrich MM; Department of Interdisciplinary Intensive Care Medicine, Vivantes Humboldt-Klinikum, Berlin, Germany.
  • Hentrich M; Department of Hematology and Oncology, Red Cross Hospital Munich, Munich, Germany.
  • Hertenstein B; Klinikum Bremen-Mitte, Bremen, Germany.
  • Hirsch HH; Transplantation & Clinical Virology, Department Biomedicine (Haus Petersplatz), University of Basel, Basel, Switzerland; Clinical Virology, Laboratory Medicine, University Hospital Basel, Basel, Switzerland; Infectious Diseases & Hospital Epidemiology, University Hospital Basel, Basel, Switz
  • Karthaus M; Department of Hematology, Oncology and Palliative Care, Klinikum Neuperlach/Klinikum Harlaching, Munich, Germany.
  • Khodamoradi Y; Department of Internal Medicine, Infectious Diseases, Goethe University Frankfurt, Frankfurt Am Main, Germany.
  • Koehler P; University of Cologne, Faculty of Medicine and University Hospital Cologne, Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I
  • Krüger W; Department of Hematology and Oncology, Stem Cell Transplantation, Palliative Care, University Hospital Greifswald, Greifswald, Germany.
  • Koldehoff M; Department of Bone Marrow Transplantation, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany; Department of Hygiene and Environmental Medicine, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
  • Krause R; Division of Infectious Diseases, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
  • Mellinghoff SC; University of Cologne, Faculty of Medicine and University Hospital Cologne, Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I
  • Penack O; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology and Tumorimmunology, Berlin, Germany.
  • Sandherr M; MVZ Penzberg, Department of Hematology and Oncology, Weilheim, Germany.
  • Seggewiss-Bernhardt R; Medizinische Klinik V, Sozialstiftung Bamberg, Bamberg, Germany; Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
  • Spiekermann K; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
  • Sprute R; University of Cologne, Faculty of Medicine and University Hospital Cologne, Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I
  • Stemler J; University of Cologne, Faculty of Medicine and University Hospital Cologne, Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I
  • Weissinger F; Department of Internal Medicine, Hematology, Oncology, Stem Cell Transplantation and Palliative Care, Evangelisches Klinikum Bethel, Bielefeld, Germany.
  • Wörmann B; Division of Haematology, Oncology and Tumor Immunology, Department of Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Wolf HH; Department of Hematology, Oncology and Hemostaseology, Südharzklinikum Nordhausen, Nordhausen, Germany.
  • Cornely OA; University of Cologne, Faculty of Medicine and University Hospital Cologne, Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany; University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I
  • Rieger CT; Hemato-Oncology Germering & Interdisciplinary Tumorcenter, Ludwig-Maximilians-University Munich, Munich, Germany.
  • von Lilienfeld-Toal M; Department of Haematology and Medical Oncology, Clinic for Internal Medicine II, University Hospital Jena, Jena, Germany; Leibniz Institute for Natural Product Research and Infection Biology, Hans Knöll Institute, Jena, Germany.
Eur J Cancer ; 181: 102-118, 2023 03.
Article in English | MEDLINE | ID: covidwho-2230357
ABSTRACT
The novel coronavirus SARS-CoV-2 and the associated infectious disease COVID-19 pose a significant challenge to healthcare systems worldwide. Patients with cancer have been identified as a high-risk population for severe infections, rendering prophylaxis and treatment strategies for these patients particularly important. Rapidly evolving clinical research, resulting in the recent advent of various vaccines and therapeutic agents against COVID-19, offers new options to improve care and protection of cancer patients. However, ongoing epidemiological changes and rise of new virus variants require repeated revisions and adaptations of prophylaxis and treatment strategies to meet these new challenges. Therefore, this guideline provides an update on evidence-based recommendations with regard to vaccination, pharmacological prophylaxis and treatment of COVID-19 in cancer patients in light of the currently dominant omicron variants. It was developed by an expert panel of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) based on a critical review of the most recent available data.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Communicable Diseases / COVID-19 / Neoplasms Type of study: Prognostic study / Reviews Topics: Long Covid / Vaccines / Variants Limits: Humans Language: English Journal: Eur J Cancer Year: 2023 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Communicable Diseases / COVID-19 / Neoplasms Type of study: Prognostic study / Reviews Topics: Long Covid / Vaccines / Variants Limits: Humans Language: English Journal: Eur J Cancer Year: 2023 Document Type: Article